DiaSorin S.p.A. DIA.MI
Composite 48/100; the shares have moved about 39% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 21/100 — a strong mark against it.
Quality ranks 61/100 — a slight point in its favour. Balance-sheet strength ranks 57/100 — a slight point in its favour. Momentum ranks 52/100 — a slight point in its favour.
Income ranks 21/100 — a strong mark against it. Growth ranks 30/100 — a moderate mark against it. Valuation ranks 40/100 — a slight mark against it.
What the company does DiaSorin S.p.A. designs, manufactures and sells immunodiagnostic and molecular diagnostic test kits across infectious diseases, oncology and metabolic disorders under the LIAISON and Simplexa brands. Its platforms include LIAISON XL/XS and xMAP, with offerings such as the LIAISON PLEX Respiratory Flex Assay and congenital CMV direct kit.
Key financials Gross margin is 65%, operating margin 20.6% and net margin 12.1%. ROE is 8.6% and ROA 6.4%. Revenue fell -8.3% while forward P/E is 16.08 versus trailing P/E of 26.12. The dividend yield is 1.8% with a payout ratio of 45.6%.
Stock health Quality score is 57.2/100 while growth is weak at 10.0/100. Momentum is mixed: +24.43% over 3 months but -19.66% over 12 months and -21.80% below the 52-week high. Income is solid at 68.2/100.
Price vs fair value The stock trades at a PREMIUM of 17.30% versus our fair-value estimate of 58.59 and a PREMIUM of 0.58% versus the analyst 12-month target of 70.45. - Forward P/E of 16.08 is well below trailing P/E of 26.12 (Valuation percentile 49.6/100) - Revenue growth of -8.3% and growth score of 10.0/100 signal weak momentum (Sideravia) - Net margin of 12.1% and ROE of 8.6% are below sector averages (Key financials)
Looking forward Analysts project a forward P/E of 16.08 and PEG of 0.26, implying earnings recovery could justify current valuation if realized. Income stability via a 1.8% dividend yield and 68.2/100 income score supports downside support.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.